Fresh concerns have emerged about the platelet studies underpinning the FDA approval of ticagrelor, AstraZeneca's ...

In a follow-up investigation into the multibillion-dollar drug ticagrelor, The BMJ has uncovered fresh concerns, this time in key platelet studies used in its FDA approval.

In a follow up investigation into the multibillion dollar drug ticagrelor, The BMJ has uncovered fresh concerns, this time in key platelet studies ...

DataM Intelligence | competitive Intelligence JAK combos, epigenetic drugs, & non-JAK agents are redefining myelofibrosis treatment offerin ...

OTC drugs aren’t always harmless. Learn the 10 dangerous over‑the‑counter drug combos that can interact fatally with ...

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

During a live event, Danielle M. Brander, MD, discussed use of zanubrutinib in high-risk chronic lymphocytic leukemia.

DataM Intelligence | competitive Intelligence ITP affects 2–5/100k yearly. New therapies like BTK, FcRn blockers aim for lasting remission, ...

Promising Systemic Sclerosis Pipeline Therapies such as Divozilimab, Avenciguat (BI 685509), Nintedanib, GSK2330811, ...

P2Y12 inhibitors like ticagrelor and clopidogrel provide a 23% lower risk of heart-related death, heart attack or stroke compared to aspirin The drugs work by making platelets less sticky ...

Therefore, inhibition of PDEs may confer a strong inhibitory effect on platelets. Two PDE inhibitors are currently in use in clinical practice, namely dipyridamole and cilostazol. Dipyridamole ...